AXQ Capital LP bought a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,355 shares of the medical research company's stock, valued at approximately $353,000.
A number of other large investors have also made changes to their positions in the company. Swedbank AB grew its stake in Amgen by 1.1% during the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company's stock valued at $173,639,000 after acquiring an additional 5,751 shares in the last quarter. Icon Wealth Advisors LLC grew its position in Amgen by 3,955.0% during the third quarter. Icon Wealth Advisors LLC now owns 174,040 shares of the medical research company's stock valued at $56,000 after purchasing an additional 169,748 shares in the last quarter. Great Valley Advisor Group Inc. increased its stake in Amgen by 130.4% in the 3rd quarter. Great Valley Advisor Group Inc. now owns 17,908 shares of the medical research company's stock valued at $5,770,000 after buying an additional 10,136 shares during the period. Truepoint Inc. purchased a new stake in Amgen in the 3rd quarter worth approximately $207,000. Finally, WESPAC Advisors LLC boosted its stake in shares of Amgen by 30.8% during the 3rd quarter. WESPAC Advisors LLC now owns 4,181 shares of the medical research company's stock valued at $1,347,000 after buying an additional 985 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.
Insider Activity
In other Amgen news, EVP David M. Reese sold 25,225 shares of the business's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the sale, the executive vice president now owns 36,922 shares of the company's stock, valued at $11,240,533.68. The trade was a 40.59 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares of the company's stock, valued at $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,341 shares of company stock worth $20,644,335. Company insiders own 0.69% of the company's stock.
Analyst Ratings Changes
A number of research firms have recently weighed in on AMGN. Piper Sandler Companies reaffirmed an "overweight" rating and issued a $310.00 price target on shares of Amgen in a research note on Thursday, January 2nd. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $324.00 target price on shares of Amgen in a research report on Friday, January 24th. Citigroup reiterated a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Piper Sandler increased their price objective on Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $314.04.
Check Out Our Latest Report on Amgen
Amgen Stock Performance
AMGN stock traded up $0.06 on Thursday, reaching $305.77. 1,736,805 shares of the company were exchanged, compared to its average volume of 2,542,168. The firm has a market capitalization of $164.26 billion, a PE ratio of 40.50, a PEG ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The stock's fifty day moving average price is $299.66 and its 200 day moving average price is $298.46. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.
Amgen Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.11%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's payout ratio is presently 126.09%.
Amgen Company Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
